Hera Biotech Raises $10M Series A to Advance Non-Surgical Endometriosis Diagnostic
Hera Biotech, a San Antonio, Texas–based biotechnology company focused on transforming women’s health through innovative diagnostic technology, has made significant progress in securing funding to support its development of a non-surgical test for endometriosis, a condition that affects millions of women worldwide and has long lacked accurate, early-stage diagnostic tools. Hera’s funding milestones underscore growing investor confidence in its mission to deliver a less invasive, more definitive diagnostic solution for a complex reproductive health challenge.
Founded in 2020 by Somer Baburek, Hera Biotech has embarked on a mission to build a better way to diagnose and stage endometriosis without requiring surgery. The company’s flagship product, MetriDx™, is designed to collect a uterine endometrial sample via an in-office procedure, similar to a Pap smear, and then apply advanced cellular analysis to identify and characterize endometrial pathology. This approach, if successfully commercialized, could reduce the time to diagnosis and eliminate the need for invasive laparoscopy for many patients.
In August 2022, Hera Biotech closed an oversubscribed $1.9 million seed funding round, a key early financial milestone for the company. The capital raised in this round was earmarked to support the completion of an in-patient human clinical study for MetriDx, expand the company’s intellectual property portfolio, and advance its regulatory strategy with the U.S. Food and Drug Administration.
The seed financing was backed by a mix of venture firms and individual supporters who believe in the importance of expanding diagnostic capability in women’s health. Among the investors participating in the round were Coyote Ventures, a venture capital firm known for investing in early-stage technology companies; Stella Angels, an angel investment group focused on empowering women-led startups; Althea Group Ventures, an early-stage life sciences investor; and the Kendra Scott Women’s Entrepreneurial Leadership Institute at the University of Texas, which supports female founders through mentorship and capital opportunities.
Hera Biotech’s oversubscribed seed round represented strong validation of both the unmet need in endometriosis diagnostics and Hera’s science-driven approach to addressing that need. The round exceeded its original fundraising target, highlighting the enthusiastic support from investors who see potential for Hera’s technology to fill a critical gap in clinical care.
Beyond the seed round, additional funding milestones have emerged as Hera Biotech advances its development path. Hera Biotech has raised an estimated total of approximately $2.1 million in funding to date, indicating ongoing investor interest and incremental capital that supports continued operations and growth.
In May 2025, new reporting indicated that Hera Biotech had reached a $10 million Series A funding round, a pivotal capital infusion aimed at accelerating clinical validation, refining its diagnostic technology and expanding the company’s commercialization and regulatory efforts toward bringing MetriDx to market. This Series A investment marks a significant funding milestone beyond the initial seed round and reflects heightened confidence from new and existing investors in Hera’s future prospects.
The $10 million Series A will enable Hera Biotech to scale up clinical trial operations, deepen its regulatory engagement, and invest in team expansion, particularly in research, development and clinical affairs. By securing this level of funding, the company can also pursue broader partnerships with healthcare systems and payers, laying the groundwork for widespread adoption once regulatory clearance is achieved and the product is commercially available.
Hera Biotech’s funding narrative occurs against the backdrop of heightened interest in women’s health innovation, a space that has historically received a smaller share of venture capital relative to other medical sectors. Hera’s success in securing capital from both gender-focused investor networks and traditional life sciences investors illustrates a growing recognition of the need for investment in diagnostic tools that address pervasive conditions like endometriosis, which can significantly impact quality of life and healthcare costs.
As Hera Biotech moves forward with its funding-backed development strategy, the company continues to build momentum toward delivering the first non-surgical, definitive test for endometriosis. With early clinical results, rising investment support and a growing team dedicated to translating scientific insights into clinical impact, Hera is positioning itself as a pioneering force in women’s health diagnostics — one with the potential to reshape the approach to diagnosing and managing endometriosis for millions of women.
